Stock Information
Halozyme Therapeutics Inc (HALO)
Ticker Symbol: HALO
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $7,920.16 mil
Piotroski score: 7
PE Ratio: 13.3002
EPS (TTM): 4.7562
Revenue (TTM): $10.16 M
Dividend Yield: N/A%
ROE: 141.55%
Latest News
-
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Thu, Dec 18, 2025 12:00 PM
-
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics
Wed, Dec 17, 2025 1:30 PM
-
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)
Mon, Dec 15, 2025 4:06 AM
Key Financials
Financial data not available
